Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735475 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
A Phase 4 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,268
- Enrollment target
NCT00735475: Completed Phase 4 study, sponsored by Seqirus.
NCT00735475 is a Phase 4 study that has completed, run by Seqirus. The registered enrollment target is 1,268 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (145% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735475, a Phase 4 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,268 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
Interventions
- BIOLOGICAL CSL Limited Influenza Virus Vaccine (Afluria®)
- BIOLOGICAL US Licensed Influenza Virus Vaccine (Fluzone®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,268 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
What the finished NCT00735475 record still lists
NCT00735475 is an interventional study that assigns participants to a tested intervention. Its 1,268 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (145% higher).
The record links to 0 conditions, and to 2 interventions - of which CSL Limited Influenza Virus Vaccine (Afluria®) is the first listed.
NCT00735475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00735475 about?
NCT00735475 is a clinical study titled "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine". The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
What is the current status of trial NCT00735475?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,268 participants. The study started on 2008-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00735475?
The interventions under investigation include: CSL Limited Influenza Virus Vaccine (Afluria®) (BIOLOGICAL), US Licensed Influenza Virus Vaccine (Fluzone®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00735475?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00735475's enrollment target sits among peer trials
1,268 62nd of 2000 higher than 1,939 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia